Jingwu Zhang Zang
Director/Board Member at HH&L ACQUISITION CO.
Net worth: 8 M $ as of 2024-03-30
Profile
Founder of I-Mab and I-Mab Biopharma (Shanghai) Co., Ltd., Jing Wu Zang is Chairman at I-Mab and Chairman & Chief Executive Officer of I-Mab Biopharma (Shanghai) Co., Ltd. (a subsidiary of I-Mab). Dr. Zang is also on the board of HH&L Acquisition Co. In his past career Dr. Zang was President & Chief Scientific Officer at Simcere Pharmaceutical Group Ltd., President & Chief Scientific Officer at BioSciKin Co., Ltd., Director-Shanghai Institute of Immunology at Shanghai Jiaotong University School of Medicine, Senior VP, Head-Research & Development at Glaxosmithkline China Ltd., Principal at Opexa Pharmaceuticals, Inc. and Professor at Baylor College of Medicine. Jing Wu Zang received a doctorate from Shanghai Jiao Tong University and a doctorate from Vrije Universiteit Brussel.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
I-MAB
4.98% | 2023-12-30 | 9,449,021 ( 4.98% ) | 8 M $ | 2024-03-30 |
Jingwu Zhang Zang active positions
| Companies | Position | Start |
|---|---|---|
| HH&L ACQUISITION CO. | Director/Board Member | 2021-02-03 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Founder | 2016-05-31 |
Former positions of Jingwu Zhang Zang
| Companies | Position | End |
|---|---|---|
| I-MAB | Chief Executive Officer | 2022-09-29 |
| SIMCERE PHARMACEUTICAL GROUP LIMITED | President | 2016-03-31 |
BioSciKin Co., Ltd.
 BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | President | 2016-03-31 |
| Glaxosmithkline China Ltd. | Chief Tech/Sci/R&D Officer | 2013-05-31 |
| Shanghai Jiao Tong University School of Medicine | Corporate Officer/Principal | 2007-03-31 |
Training of Jingwu Zhang Zang
| Shanghai Jiao Tong University | Doctorate Degree |
| Vrije Universiteit Brussel | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SIMCERE PHARMACEUTICAL GROUP LIMITED | Health Technology |
| I-MAB | Health Technology |
| Private companies | 7 |
|---|---|
| Opexa Pharmaceuticals, Inc. | Health Technology |
Institut Pasteur de Shanghai
 Institut Pasteur de Shanghai Miscellaneous Commercial ServicesCommercial Services Institut Pasteur de Shanghai operates as a non-profit life sciences organization. The private company is based in Shanghai, China. | Commercial Services |
| Glaxosmithkline China Ltd. | |
| The Institute of Health Sciences | |
BioSciKin Co., Ltd.
BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
HH&L Acquisition Co.
 HH&L Acquisition Co. Financial ConglomeratesFinance HH&L Acquisition Co. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 4, 2020 and is headquartered in Hong Kong. | Finance |
- Stock Market
- Insiders
- Jingwu Zhang Zang
